{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:53:58Z","timestamp":1793915638601,"version":"4.8.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability. Efgartigimod, a human IgG1 Fc fragment, has recently been approved for adult CIDP, but its safety and efficacy in pediatric CIDP remain unstudied. We retrospectively analyzed two pediatric patients with CIDP who received efgartigimod treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Age at onset was 1.5 and 3.4 years; disease duration before efgartigimod was 1.5 and 3.2 years; and age at initiation was 3.0 and 6.6 years. Prior treatments included corticosteroids, maintenance intravenous immunoglobulin, mycophenolate mofetil, and rituximab in one patient, and corticosteroids plus maintenance intravenous immunoglobulin in the other. Both initiated efgartigimod due to uncontrolled relapses. At final follow-up (8 months), both showed improvement in Medical Research Council (MRC) sum scores and Inflammatory Neuropathy Cause and Treatment (INCAT) scores. One patient experienced a single relapse; the other remained relapse-free. Two mild, self-limited adverse events occurred: upper respiratory tract infection in one and transient alanine aminotransferase elevation in the other.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first report of efgartigimod use in pediatric patients with CIDP. Efgartigimod was generally well tolerated, and some clinical improvements were observed in this population. However, given the small sample size, these findings should be considered preliminary and require confirmation in larger, prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1741057","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:32Z","timestamp":1768204652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanping","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houliang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/ITT.S388151","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: current therapeutic approaches and future outlooks","volume":"13","author":"Rajabally","year":"2024","journal-title":"Immunotargets Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.128132","article-title":"Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population","volume":"79","author":"Iijima","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2012.09.008","article-title":"Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series","volume":"23","author":"McMillan","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-024-02557-2","article-title":"Differentiating recurrent Guillain-Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review","volume":"124","author":"Inan","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","article-title":"Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease","volume":"102","author":"Rodr\u00edguez","year":"2019","journal-title":"J Autoimmun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1741057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:34Z","timestamp":1768204654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1741057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2025.1741057"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1741057","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1741057"}}